Strongyloides infection manifested during immunosuppressive therapy for SARS-CoV-2 pneumonia.

Valentina MarcheseVerena CrosatoMaurizio GullettaFilippo CastelnuovoGraziella CristiniAlberto MatteelliFrancesco Castelli

Published in: Infection (2020)

We report the first case of S. stercoralis infection following an 11-day treatment with high-dose steroids and Tocilizumab for severe COVID-19. Clinicians should be aware of the risk of strongyloidiasis as a complication of the treatment for severe COVID-19.

Keyphrases

sars cov
coronavirus disease
high dose
respiratory syndrome coronavirus
rheumatoid arthritis
low dose
intensive care unit
combination therapy
replacement therapy
acute respiratory distress syndrome
smoking cessation